English

ARIDIS PHARMACEUTICALS, INC.

EDGAR

ARDS Quarterly report (10-Q) · filed 2023-11-06

32 filing records in this dataset, filed from 2018-07-18 to 2023-11-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

417 thousand USD

2023 Q3 · USD

Exact inputs and evidence

Revenue: 417000 USD Source

Operating margin

-208.39%

2023 Q3 · %

Exact inputs and evidence

Operating Income: -869000 USD Source
Revenue: 417000 USD Source

Operating cash flow

-983 thousand USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -9328000 USD Source
Operating Cash Flow: -8345000 USD Source

Cash and cash equivalents: 35 thousand USD 2023-09-30 Source
Exact value

35000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 44.6 million shares 2023-09-30 Source
Exact value

44574021 shares

Reported share-count change

151.81% · 26.9 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

17701592 shares · 2022-09-30· Source
44574021 shares · 2023-09-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-06.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2022-12-31
Operating income: 2 of 11 periods available· newest 2022-12-31
Net income: 2 of 11 periods available· newest 2022-12-31
Operating cash flow: 2 of 11 periods available· newest 2022-12-31
Capital expenditure: 2 of 11 periods available· newest 2022-12-31
Total assets: 2 of 11 periods available· newest 2022-12-31
Total liabilities: 2 of 11 periods available· newest 2022-12-31
Current assets: 2 of 11 periods available· newest 2022-12-31
Current liabilities: 2 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2022-12-31
long term debt: No compatible figures in this window
Shares outstanding: 2 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+101.4%

Prior period

USD 1.54 million

2021-01-01 – 2021-12-31
Current period

USD 3.09 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

3091000 − 1535000 = 1556000 USD

1535000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
3091000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Year-over-year change in Revenue: 1556000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 3091000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2066838 Filing: 000149315223018590 Input fundies:Revenue: 1535000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2067662 Filing: 000149315223018590
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 11.82 million

Prior period

−USD 42.19 million

2021-01-01 – 2021-12-31
Current period

−USD 30.37 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-30371000 − -42193000 = 11822000 USD

-42193000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-30371000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Year-over-year change in Net income: 11822000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -30371000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2220765 Filing: 000149315223018590 Input fundies:NetIncome: -42193000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2221617 Filing: 000149315223018590
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 6.19 million

Prior period

−USD 22.94 million

2021-01-01 – 2021-12-31
Current period

−USD 29.13 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-29127000 − -22936000 = -6191000 USD

-22936000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-29127000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Year-over-year change in Operating cash flow: -6191000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -29127000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2259085 Filing: 000149315223018590 Input fundies:OperatingCashFlow: -22936000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2260040 Filing: 000149315223018590
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-84.5%

Prior period

USD 530,000

2021-01-01 – 2021-12-31
Current period

USD 82,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

82000 − 530000 = -448000 USD

530000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
82000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Year-over-year change in Capital expenditure: -448000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 82000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2263137 Filing: 000149315223018590 Input fundies:CapitalExpenditure: 530000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2264079 Filing: 000149315223018590
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 3.09 million 100% of revenue
Operating costs Derived USD 33.08 million 1,070% of revenue
Operating income −USD 29.99 million −970% of revenue
Tax, interest and other Derived USD 378,000 12% of revenue
Net income −USD 30.37 million −983% of revenue

Cash

Operating cash flow −USD 29.13 million −942% of revenue
Capital expenditure USD 82,000 2.7% of revenue
Free cash flow Derived −USD 29.21 million −945% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 2,882% of revenue.
2022 Operating loss: operating costs were 1,070% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	1535000	44246000 Derived	-42711000	-518000 Derived	-42193000	-23466000 Derived	Source 2021-01-01 – 2021-12-31: 1535000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -42711000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -42193000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -22936000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 530000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	3091000	33084000 Derived	-29993000	378000 Derived	-30371000	-29209000 Derived	Source 2022-01-01 – 2022-12-31: 3091000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -29993000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -30371000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -29127000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 82000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 3.1M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	1535000	Revenue: 1535000 Open source
20222022-12-31	Revenue	3091000	Revenue: 3091000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

101.4% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 1535000 Open source
20222022-12-31	Year over year	101.4%	Revenue: 3091000 Open source Revenue: 1535000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -970.3% 2022

Net margin -982.6% 2022

Free cash flow margin -945% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-2,782.5%	Operating Income: -42711000 Open source Revenue: 1535000 Open source
20222022-12-31	Operating margin	-970.3%	Operating Income: -29993000 Open source Revenue: 3091000 Open source
20212021-12-31	Net margin	-2,748.7%	Net Income: -42193000 Open source Revenue: 1535000 Open source
20222022-12-31	Net margin	-982.6%	Net Income: -30371000 Open source Revenue: 3091000 Open source
20212021-12-31	Free cash flow margin	-1,528.7%	Revenue: 1535000 Open source Operating Cash Flow: -22936000 Open source Capital Expenditure: 530000 Open source
20222022-12-31	Free cash flow margin	-945%	Revenue: 3091000 Open source Operating Cash Flow: -29127000 Open source Capital Expenditure: 82000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -29.1M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-22936000	Operating Cash Flow: -22936000 Open source
20222022-12-31	Operating cash flow	-29127000	Operating Cash Flow: -29127000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -29.2M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-23466000	Operating Cash Flow: -22936000 Open source Capital Expenditure: 530000 Open source
20222022-12-31	Free cash flow	-29209000	Operating Cash Flow: -29127000 Open source Capital Expenditure: 82000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

264.9% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	148.9%	Total Liabilities: 39906000 Open source Total Assets: 26796000 Open source
20222022-12-31	Liabilities / assets	264.9%	Total Liabilities: 38927000 Open source Total Assets: 14695000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.32× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	0.73×	Current Assets: 24390000 Open source Current Liabilities: 33348000 Open source
20222022-12-31	Current assets / current liabilities	0.32×	Current Assets: 11626000 Open source Current Liabilities: 36898000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2021 2021-01-01 – 2021-12-31	−USD 42.19 million Exact value Exact value: -42193000 USD 2021-01-01 – 2021-12-31: -42193000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARIDIS PHARMACEUTICALS, INC. · 2021-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Net Income: -42193000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42193000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2221617 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.	−USD 22.94 million Exact value Exact value: -22936000 USD 2021-01-01 – 2021-12-31: -22936000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARIDIS PHARMACEUTICALS, INC. · 2021-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Operating Cash Flow: -22936000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22936000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2260040 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.	USD 530,000 Exact value Exact value: 530000 USD 2021-01-01 – 2021-12-31: 530000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARIDIS PHARMACEUTICALS, INC. · 2021-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Capital Expenditure: 530000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 530000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2264079 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.	−USD 23.47 million Calculation and evidence -22936000 − 530000 USD Exact free cash flow: -23466000 USD 2021-01-01 – 2021-12-31: -22936000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 530000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARIDIS PHARMACEUTICALS, INC. · 2021-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Free cash flow: -23466000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22936000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2260040 Filing: 000149315223018590 Input fundies:CapitalExpenditure: 530000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2264079 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 30.37 million Exact value Exact value: -30371000 USD 2022-01-01 – 2022-12-31: -30371000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Net Income: -30371000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30371000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2220765 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.	−USD 29.13 million Exact value Exact value: -29127000 USD 2022-01-01 – 2022-12-31: -29127000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Operating Cash Flow: -29127000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29127000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2259085 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.	USD 82,000 Exact value Exact value: 82000 USD 2022-01-01 – 2022-12-31: 82000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Capital Expenditure: 82000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 82000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2263137 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.	−USD 29.21 million Calculation and evidence -29127000 − 82000 USD Exact free cash flow: -29209000 USD 2022-01-01 – 2022-12-31: -29127000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 82000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ARIDIS PHARMACEUTICALS, INC. · 2022-12-31 ARIDIS PHARMACEUTICALS, INC. (edgar:1614067) Free cash flow: -29209000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:20:29Z Snapshot: 8972d51dbced7677488b6d96e7118a31ff750baffa0007a69862ee6f83c81394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1614067?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29127000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2259085 Filing: 000149315223018590 Input fundies:CapitalExpenditure: 82000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1614067/000149315223018590/form10-k.htm#2263137 Filing: 000149315223018590 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

32 filings · 1,814 latest values · 1,814 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001614067, 1614067, ARDS, edgar:1614067

Also known as ARIDIS PHARMACEUTICALS, INC., Aridis Pharmaceuticals, Inc., Aridis Pharmaceuticals, Inc.

ARIDIS PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation